<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer

Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, +12

Oncotarget

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

Shunsuke Kitajima, Tetsuo Tani, Benjamin F. Springer, +25

Cancer Cell

MedicineMps1 InhibitionTumor SuppressorCancer BiologyCell Biology +2

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Erik H. Knelson, Elena V. Ivanova, Mubin Tarannum, +46

Cancer Immunology Research

Cancer ResearchCancer ImmunosurveillanceMedicineImmunologyTumor Immunity +11

<i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity

Tetsuo Tani, Haritha Mathsyaraja, Marco Campisi, +24

Cancer Discovery

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

Masayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani, +11

Molecular Cancer Research

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

Kartik Sehgal, Andrew Portell, Elena V. Ivanova, +25

Journal of Clinical Investigation

Cell TherapyPd-1 BlockadeImmunologyImmune RegulationImmunoediting +22

Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer Cells

Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto, +10

Molecular Cancer Therapeutics

Analysis of five cases with neurogenic stuttering following brain injury in the basal ganglia

Tetsuo Tani, Yasujiro Sakai

Journal of Fluency Disorders

NeurorehabilitationNeuropsychologyNeurological DisorderNeurological InjuryNeuroanatomy +13

Tumor-Derived cGAMP Regulates Activation of the Vasculature

Marco Campisi, Shriram K. Sundararaman, Sarah E. Shelton, +17

Frontiers in Immunology

ImmunologyImmunologic MechanismInnate ImmunityImmunotherapyTumor Biology +16

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

Hanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto, +11

Lung Cancer

Insertion MutationsCetuximab Combination TherapyNon-small-cell Lung CancerMedicinePathology +6